Fabrice Chouraqui will become CEO of Pharming Group N.V. (Euronext:PHARM) pending the approval of the company’s shareholders at a March 4 extraordinary meeting. Chouraqui, a CEO-partner of Flagship Pioneering, will succeed Sijmen de Vries if approved.

Friends of Cancer Research appointed FDA veteran Janet Woodcock and attorney Paul Kim to its board. Woodcock was most recently acting FDA commissioner, then principal deputy commissioner at the agency; Kim led the FDA and federal government strategies practices at Foley Hoag LLP, where he worked for 20 years.

Verastem Inc. (NASDAQ:VSTM) named Matthew Ros COO. Ros was CEO of Fore Biotherapeutics Inc. before which he was COO at Epizyme Inc.

Richard Law disclosed on LinkedIn that he’s stepped down as CBO of Exscientia plc., which combined with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Law joined the company in 2020 from Evotec SE (Xetra:EVT; NASDAQ:EVO), where he was SVP of business development.

Health technology company Medtronic plc (NYSE:MDT) hired Thierry Piéton as CFO, effective March 3. Medtronic added that interim CFO Gary Corona will become SVP, corporate finance effective the same date. Piéton was CFO of Renault Group.

Psilocybin company Compass Pathways plc (NASDAQ:CMPS) named Steve Levine to the newly created role of chief patient officer. Levine joined the company in 2020 as SVP of patient access.

Kincell Bio LLC, a cell therapy CDMO, named Chair Mark Bamforth CEO. Bamforth founded and was CEO of three other CDMOs — Arranta Bio Holdings LLC, Brammer Bio and Gallus Biopharmaceuticals.

Richard O’Neal took to LinkedIn to announce his retirement as SVP, Market Access of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), effective Jan. 24. O’Neal identified Don Sawyer, formerly of Stemline Therapeutics Inc., as his successor.

https://www.biocentury.com/article/654768/fabrice-chouraqui-to-become-ceo-of-pharming